CD8A and cancer: Moreover, the ability of EBV to express T cell-specific antigens implies that EBV itself has potential applications in cancer immunotherapy, underscored by the evidence that ectopically expressed EBV latent membrane protein 1 (LMP1) induces multiple cellular tumor-associated antigens (TAAs) that trigger a robust CD4/CD8 cytotoxic response in EBV-unrelated cancers [49,50].